Department of Cardiology, Yijishan Hospital of Wannan Medical College, Wuhu, People's Republic of China.
Ir J Med Sci. 2011 Jun;180(2):379-85. doi: 10.1007/s11845-011-0687-3. Epub 2011 Feb 1.
The electrophysiological consequences of mesenchymal stem cell (MSC) therapy in ischemic heart disease have not been fully understood.
Swine myocardial infarction (MI) model by intracoronary balloon occlusion received MSC solution or 0.9% NaCl. Six weeks later, heart rate turbulence (HRT), dispersion of action potential durations (APD) and repolarization time (RT) (APDd and RTd), slope of APD reconstitution curve and programmed electrical stimulation were used to evaluate the ventricular arrhythmic risks.
MSC treatment could significantly ameliorate the abnormal HRT, APD(90), APDd, RT and RTd. The slope of APD reconstitution curve in MSC group was higher than control group but lower than MI group. MSC therapy markedly reduced inducible malignant ventricular arrhythmias (VAs), and improved impaired cardiac performances and cardiac fibrosis.
This study provides strong evidence that MSC infusion via intracoronary route does not cause VAs but tends to reduce the risk of malignant VAs.
间充质干细胞（MSC）治疗缺血性心脏病的电生理后果尚未完全被理解。
通过冠状动脉内球囊闭塞建立猪心肌梗死（MI）模型，接受 MSC 溶液或 0.9%生理盐水治疗。6 周后，采用心率震荡（HRT）、动作电位时程（APD）和复极时间（RT）（APDd 和 RTd）离散度、APD 再极化曲线斜率和程控电刺激来评估室性心律失常风险。
MSC 治疗可显著改善异常的 HRT、APD（90）、APDd、RT 和 RTd。MSC 组的 APD 再极化曲线斜率高于对照组，但低于 MI 组。MSC 治疗可显著减少诱发性恶性室性心律失常（VAs），改善受损的心脏功能和心脏纤维化。
本研究提供了强有力的证据，表明经冠状动脉内输注 MSC 不会引起 VAs，但可能降低恶性 VAs 的风险。
